{"id":31880,"date":"2025-04-16T10:44:40","date_gmt":"2025-04-16T02:44:40","guid":{"rendered":"https:\/\/flcube.com\/?p=31880"},"modified":"2025-04-16T10:44:41","modified_gmt":"2025-04-16T02:44:41","slug":"us-commerce-department-launches-section-232-probe-on-pharma-imports-and-national-security","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31880","title":{"rendered":"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security"},"content":{"rendered":"\n<p>The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the impact of pharmaceutical and pharmaceutical ingredient imports on national security, following President Donald Trump\u2019s recent statements on potential tariffs for the pharma industry. The investigation, effective from April 1, 2025, seeks to determine whether tariffs or quotas on pharmaceuticals are necessary to protect national security. A similar probe has also been launched for the semiconductors industry.<\/p>\n\n\n\n<p><strong>Section 232 Background<\/strong><br>Section 232 of the Trade Expansion Act of 1962 empowers the president or department\/agency heads to request the DoC to investigate whether certain imports pose national security risks. The DoC has 270 days to complete the investigation. This provision allows the president to impose tariffs or trade restrictions without congressional approval and has been frequently used by the Trump administration, notably for steel and aluminum tariffs in 2018.<\/p>\n\n\n\n<p><strong>Scope of the Pharmaceutical Investigation<\/strong><br>The investigation will focus on finished generic and non-generic drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients (APIs) and key starting materials, and their derivative products. It will also assess:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Current and projected demand for pharmaceuticals and ingredients in the US;<\/li>\n\n\n\n<li>Domestic production capacity to meet demand;<\/li>\n\n\n\n<li>The role of foreign supply chains in fulfilling US needs;<\/li>\n\n\n\n<li>Impact of foreign government subsidies and predatory trade practices;<\/li>\n\n\n\n<li>Economic effects of artificially suppressed drug prices due to unfair trade practices;<\/li>\n\n\n\n<li>Potential for foreign export restrictions and the risk of pharmaceuticals being used as geopolitical leverage;<\/li>\n\n\n\n<li>Feasibility of expanding domestic capacity to reduce import reliance.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025-06587.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025-06587.\"><\/object><a id=\"wp-block-file--media-061ee892-61ec-42f8-9af8-e9967763e8cb\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025-06587.pdf\">2025-06587<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2025-06587.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-061ee892-61ec-42f8-9af8-e9967763e8cb\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":31882,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11,4],"tags":[31],"class_list":["post-31880","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-policy-regulatory","tag-generic-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the impact of pharmaceutical and pharmaceutical ingredient imports on national security, following President Donald Trump\u2019s recent statements on potential tariffs for the pharma industry. The investigation, effective from April 1, 2025, seeks to determine whether tariffs or quotas on pharmaceuticals are necessary to protect national security. A similar probe has also been launched for the semiconductors industry.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31880\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security\" \/>\n<meta property=\"og:description\" content=\"The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the impact of pharmaceutical and pharmaceutical ingredient imports on national security, following President Donald Trump\u2019s recent statements on potential tariffs for the pharma industry. The investigation, effective from April 1, 2025, seeks to determine whether tariffs or quotas on pharmaceuticals are necessary to protect national security. A similar probe has also been launched for the semiconductors industry.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31880\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-16T02:44:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-16T02:44:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/fdf50569ed34703c64f6f11ee6e43f4b.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31880#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31880\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security\",\"datePublished\":\"2025-04-16T02:44:40+00:00\",\"dateModified\":\"2025-04-16T02:44:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31880\"},\"wordCount\":264,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31880#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/fdf50569ed34703c64f6f11ee6e43f4b.webp\",\"keywords\":[\"Generic drugs\"],\"articleSection\":[\"Company\",\"Drug\",\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31880#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31880\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31880\",\"name\":\"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31880#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31880#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/fdf50569ed34703c64f6f11ee6e43f4b.webp\",\"datePublished\":\"2025-04-16T02:44:40+00:00\",\"dateModified\":\"2025-04-16T02:44:41+00:00\",\"description\":\"The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the impact of pharmaceutical and pharmaceutical ingredient imports on national security, following President Donald Trump\u2019s recent statements on potential tariffs for the pharma industry. The investigation, effective from April 1, 2025, seeks to determine whether tariffs or quotas on pharmaceuticals are necessary to protect national security. A similar probe has also been launched for the semiconductors industry.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31880#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31880\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31880#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/fdf50569ed34703c64f6f11ee6e43f4b.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/fdf50569ed34703c64f6f11ee6e43f4b.webp\",\"width\":1112,\"height\":627,\"caption\":\"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31880#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security - Insight, China&#039;s Pharmaceutical Industry","description":"The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the impact of pharmaceutical and pharmaceutical ingredient imports on national security, following President Donald Trump\u2019s recent statements on potential tariffs for the pharma industry. The investigation, effective from April 1, 2025, seeks to determine whether tariffs or quotas on pharmaceuticals are necessary to protect national security. A similar probe has also been launched for the semiconductors industry.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31880","og_locale":"en_US","og_type":"article","og_title":"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security","og_description":"The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the impact of pharmaceutical and pharmaceutical ingredient imports on national security, following President Donald Trump\u2019s recent statements on potential tariffs for the pharma industry. The investigation, effective from April 1, 2025, seeks to determine whether tariffs or quotas on pharmaceuticals are necessary to protect national security. A similar probe has also been launched for the semiconductors industry.","og_url":"https:\/\/flcube.com\/?p=31880","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-16T02:44:40+00:00","article_modified_time":"2025-04-16T02:44:41+00:00","og_image":[{"width":1112,"height":627,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/fdf50569ed34703c64f6f11ee6e43f4b.webp","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31880#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31880"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security","datePublished":"2025-04-16T02:44:40+00:00","dateModified":"2025-04-16T02:44:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31880"},"wordCount":264,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31880#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/fdf50569ed34703c64f6f11ee6e43f4b.webp","keywords":["Generic drugs"],"articleSection":["Company","Drug","Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31880#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31880","url":"https:\/\/flcube.com\/?p=31880","name":"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31880#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31880#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/fdf50569ed34703c64f6f11ee6e43f4b.webp","datePublished":"2025-04-16T02:44:40+00:00","dateModified":"2025-04-16T02:44:41+00:00","description":"The US Department of Commerce (DoC) has initiated a Section 232 investigation to evaluate the impact of pharmaceutical and pharmaceutical ingredient imports on national security, following President Donald Trump\u2019s recent statements on potential tariffs for the pharma industry. The investigation, effective from April 1, 2025, seeks to determine whether tariffs or quotas on pharmaceuticals are necessary to protect national security. A similar probe has also been launched for the semiconductors industry.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31880#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31880"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31880#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/fdf50569ed34703c64f6f11ee6e43f4b.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/fdf50569ed34703c64f6f11ee6e43f4b.webp","width":1112,"height":627,"caption":"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31880#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"US Commerce Department Launches Section 232 Probe on Pharma Imports and National Security"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/fdf50569ed34703c64f6f11ee6e43f4b.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31880","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31880"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31880\/revisions"}],"predecessor-version":[{"id":31883,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31880\/revisions\/31883"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31882"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31880"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31880"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31880"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}